Battlefield Pain Management � Analgesic
Defense Health Agency · DEFENSE HEALTH AGENCY
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HT942726RE009 in this department, oldest first.
- Apr 23, 2026Pre-solicitationOpen
- Jun 29, 2026SolicitationOpen
- Jul 23, 2026 · this noticeSolicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
This Request for Prototype Proposal (RPP) is being issued under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022 by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency, Portfolio Acquisition Executive Medical Products (PAE MP), Warfighter Protection and Acute Care Project Management Office (WPAC PMO) located in Frederick, Maryland, at Fort Detrick. The requirement is for Analgesic Product for Battlefield Use. Please see the attached RPP and attachments for additional information. Amendment 0001 The purpose of Amendment 000… (show all)
1 is to: 1. Amend the Request for Prototype Proposal (RPP) as follows: - Extend the proposal due date from 30 July 2026 to 14 August 2026 (RPP Amendment 0001, page 1 and page 17). No additional questions/phone calls regarding the RPP will be accepted. - Update the word �drug� to �product� to align with the language (RPP Amendment 0001, page 2, section 1.1, third paragraph) - Clarify language regarding the Spend Plan (RPP Amendment 0001, page 13, section 3.5 Volume III: Administrative and Cost Volume, Attachment E � Cost Sheet Template with priced milestones, first paragraph). - Add additional Vendor requirements (RPP Amendment 0001, page 15, section 3.5 Volume III: Administrative and Cost Volume, Other Administrative Requirements). 2. Amend the RPP, Attachment A � Statement of Objectives (SOO) as follows: - Update the Revised Date (page 1). - Update language throughout to clarify the Government�s intent regarding drug versus product. - page 1, section 1. Purpose/Objective, second and third paragraphs - page 2, section 4 Objectives, second, third and fifth paragraphs - page 3, section 4 Objectives, first paragraph - page 5, Desirable prototype characteristics and performance, first paragraph - Revise the following Desirable prototype characteristics and performance: (2), (6), (9), and (13) (page 5 and page 6). - Revise the following Deliverables: Deliverable 3 and Deliverable 12 (page 7 and page 9, respectively). 3. Answer questions received from potential performers (see RPP Amendment 0001, Attachment 1). There are no other changes.
Who won similar work
5 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Defense Health Agency), same NAICS 541714.
Single-winner award sizes (5): middle half $273K to $11.5M, median $2.0M; range $110K to $72.4M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CHENEGA SERVICES & FEDERAL SOLUTIONS, LLC | 1 | $72.4M | May 20, 2026 |
| CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC | 1 | $11.5M | Sep 29, 2025 |
| MAPP BIOPHARMACEUTICAL, INC. | 1 | $2.0M | Jun 4, 2025 |
| ILLUMINA, INC. · $ILMN · $4.5B | 1 | $273K | May 30, 2026 |
| POTOMAC AFFINITY PROTEINS, LLC | 1 | $110K | Jul 9, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $ILMN reported $4.5B revenue in FY2025. The median single-winner award in these 5 past awards, $2.0M, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- May 30, 2026ILLUMINA, INC.$273KIllumina Urinary Pathogen Identification (ID)/Antimicrobial Resistance (AMR) Enrichment Kit (UPIP), (1) Respiratory Pathogen ID/AMR Enrichment Kit Set A,
- May 20, 2026CHENEGA SERVICES & FEDERAL SOLUTIONS, LLC$72.4MScientific, Technical Research and Project Management Support Services for USAMRIID
- Sep 29, 2025CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC$11.5MScientific and Technical Research Support Services
- Jul 9, 2025POTOMAC AFFINITY PROTEINS, LLC$110KUsing Protease Cascades to Detect Protein Targets
- Jun 4, 2025MAPP BIOPHARMACEUTICAL, INC.$2.0Mhuman-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
Competitive landscape
For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff since 2024 (1 filings)
- 0 of their lobbyists list a past Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 1 bills named on the past winners' lobbying filings
- 32 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 4 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.